President-elect Donald Trump has attempted to be more conciliatory than he was during his campaign, signaling flexibility on some of his most extreme campaign promises. For example, Trump 2.0 has been downright cuddly to pharma after frequently criticizing its pricing practices during his campaign.
A health-care plan on his transition website has no mention of high drug prices, with only vague bullet points on supporting innovative research and softening the FDA. Biopharma stocks had plunged this year due partly to fears that a Hillary Clinton presidency might usher in drug-price controls; the Nasdaq Biotech Index was down as much as 26 percent for the year the week before the election. The index spiked 9 percent on the Wednesday after Trump won the election, its biggest jump since 2008.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.